



## ImmunoGen Announces Webcast of Presentation and Q&A at the 36th Annual J.P. Morgan Healthcare Conference

January 2, 2018

WALTHAM, Mass.--(BUSINESS WIRE)--Jan. 2, 2018-- [ImmunoGen, Inc.](http://www.immunogen.com) (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, will present at the upcoming 36<sup>th</sup> Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation is scheduled for 8:30am PT (11:30am ET) on January 10, 2018.

Following the presentation, Mr. Enyedy will be joined by other members of ImmunoGen's management team for a question-and-answer session at 9:00am PT (12:00pm ET).

A webcast of the presentation and question-and-answer session will be accessible live through the "Investors" section of the Company's website, [www.immunogen.com](http://www.immunogen.com); a replay will be available in the same location for approximately two weeks.

### About ImmunoGen, Inc.

ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. The Company's lead product candidate, mirvetuximab soravtansine, is in a Phase 3 trial for FR<sup>+</sup>-positive platinum-resistant ovarian cancer, and is in a Phase 1b/2 trial in combination regimens for earlier-stage disease. ImmunoGen has three additional clinical-stage product candidates, two of which are being developed in collaboration with Jazz Pharmaceuticals. ImmunoGen's ADC technology is also used in Roche's marketed product, Kadcyła<sup>®</sup>, and in programs in development by Amgen, Bayer, Biotest, CytomX, Debiopharm, Lilly, Novartis, Sanofi and Takeda. More information about the Company can be found at [www.immunogen.com](http://www.immunogen.com).

Kadcyła<sup>®</sup> is a registered trademark of Genentech, a member of the Roche Group.

*This press release includes forward-looking statements. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. It should be noted that there are risks and uncertainties related to the development of novel anticancer products, including risks related to preclinical and clinical studies, their timings and results. A review of these risks can be found in ImmunoGen's Transition Report on Form 10-K for the fiscal year ended December 31, 2016 and other reports filed with the Securities and Exchange Commission.*

View source version on businesswire.com: <http://www.businesswire.com/news/home/20180102005074/en/>

Source: ImmunoGen, Inc.

For Investors

ImmunoGen, Inc.

Sarah Kiely, 781-895-0600

[sarah.kiely@immunogen.com](mailto:sarah.kiely@immunogen.com)

or

For Media

ImmunoGen, Inc.

Courtney O'Konek, 781-895-0600

[courtney.okonek@immunogen.com](mailto:courtney.okonek@immunogen.com)

or

FTI Consulting Inc.

Robert Stanislaro, 212-850-5657

[robert.stanislaro@fticonsulting.com](mailto:robert.stanislaro@fticonsulting.com)